title: Adhesion molecule expression by bone marrow CD34-positive cells in aplastic anemia before and after immunosuppressive therapy.
abstract: Appropriate adhesion between bone marrow stem cells and the marrow microenvironment is necessary for hematopoiesis, since signals that promote maturation or apoptosis are transmitted from stromal cells to stem cells. In aplastic anemia (AA), interferon-gamma produced by stromal cells has more influence on the pathogenesis of marrow failure than interferon-gamma produced by lymphocytes. We evaluated the expression of cell adhesion molecules, such as very late antigen-4 (CD49d), and -5 (CD49e) or c-kit receptor (CD117), by CD34-positive bone marrow cells in patients with AA who achieved hematological complete remission after immunosuppressive therapy. Before treatment, CD34-positive cells showed markedly higher expression of CD49d and CD49e than cells from healthy controls, indicating the strong adhesion of stem cells to the bone marrow stroma. Expression of CD49d and CD49e was significantly decreased, reaching normal levels, after hematological recovery. These findings suggest that changes in adhesion molecule expression by stem cells are important in the pathology of AA.
authors.affiliation: Central Clinical Laboratory, Jikei University Hospital, Tokyo, Japan. ken.kaito@jikei.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Kaito
authors.forename: H
authors.initials: H
authors.lastname: Otsubo
authors.forename: Y
authors.initials: Y
authors.lastname: Ogasawara
authors.forename: T
authors.initials: T
authors.lastname: Shimada
authors.forename: N
authors.initials: N
authors.lastname: Usui
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D018952:Antigens, CD34 / Q000032:analysis; D017209:Apoptosis; D001853:Bone Marrow / Q000473:pathology*; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D005786:Gene Expression Regulation; D006412:Hematopoietic Stem Cells / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D039441:Integrin alpha4 / Q000096:biosynthesis / Q000235:genetics; D039482:Integrin alpha5 / Q000096:biosynthesis / Q000235:genetics; D007371:Interferon-gamma / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis / Q000235:genetics; D012074:Remission Induction; D019014:fas Receptor / Q000096:biosynthesis / Q000235:genetics
chemical_list: D018952:Antigens, CD34; D015815:Cell Adhesion Molecules; D007166:Immunosuppressive Agents; D039482:Integrin alpha5; D019014:fas Receptor; D039441:Integrin alpha4; D007371:Interferon-gamma; D019009:Proto-Oncogene Proteins c-kit